Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study

Ocskay, Klementina, Juhász, Márk Félix, Farkas, Nelli, Zádori, Noémi, Szakó, Lajos, Szakács, Zsolt, Szentesi, Andrea, Eross, Bálint, Miklós, Emoke, Zemplényi, Antal, Birkás, Béla, Csathó, Árpád, Hartung, István, Nagy, Tamás, Czopf, László, Izbéki, Ferenc, Gajdán, László, Papp, Mária, Czakó, László, Illés, Dóra, Marino, Marco V, Mirabella, Antonello, Malecka-Panas, Ewa, Zatorski, Hubert, Susak, Yaroslav, Opalchuk, Kristina, Capurso, Gabriele, Apadula, Laura, Gheorghe, Cristian, Saizu, Ionut Adrian, Petersen, Ole H. ORCID: https://orcid.org/0000-0002-6998-0380, de-Madaria, Enrique, Rosendahl, Jonas, Párniczky, Andrea and Hegyi, Péter 2022. Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study. BMJ Open 12 (1) , e050821. 10.1136/bmjopen-2021-050821

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (816kB) | Preview

Abstract

Background/objectives Acute recurrent pancreatitis (ARP) due to alcohol and/or tobacco abuse is a preventable disease which lowers quality of life and can lead to chronic pancreatitis. The REAPPEAR study aims to investigate whether a combined patient education and cessation programme for smoking and alcohol prevents ARP. Methods and analysis The REAPPEAR study consists of an international multicentre randomised controlled trial (REAPPEAR-T) testing the efficacy of a cessation programme on alcohol and smoking and a prospective cohort study (REAPPEAR-C) assessing the effects of change in alcohol consumption and smoking (irrespective of intervention). Daily smoker patients hospitalised with alcohol-induced acute pancreatitis (AP) will be enrolled. All patients will receive a standard intervention priorly to encourage alcohol and smoking cessation. Participants will be subjected to laboratory testing, measurement of blood pressure and body mass index and will provide blood, hair and urine samples for later biomarker analysis. Addiction, motivation to change, socioeconomic status and quality of life will be evaluated with questionnaires. In the trial, patients will be randomised either to the cessation programme with 3-monthly visits or to the control group with annual visits. Participants of the cessation programme will receive a brief intervention at every visit with direct feedback on their alcohol consumption based on laboratory results. The primary endpoint will be the composite of 2-year all-cause recurrence rate of AP and/or 2-year all-cause mortality. The cost-effectiveness of the cessation programme will be evaluated. An estimated 182 participants will be enrolled per group to the REAPPEAR-T with further enrolment to the cohort.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Additional Information:	This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license
Publisher:	BMJ Publishing Group
ISSN:	2044-6055
Date of First Compliant Deposit:	26 January 2022
Date of Acceptance:	12 November 2021
Last Modified:	10 May 2023 02:31
URI:	https://orca.cardiff.ac.uk/id/eprint/146944

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item